GALT Galectin Therapeutics Inc

Price (delayed)

$3.34

Market cap

$206.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.74

Enterprise value

$252.84M

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a ...

Highlights

Galectin Therapeutics's quick ratio has decreased by 15% QoQ but it has increased by 15% YoY

Galectin Therapeutics's EPS has decreased by 14% YoY but it has increased by 2.6% QoQ

GALT's equity has dropped by 83% year-on-year and by 18% since the previous quarter

The debt has soared by 80% YoY and by 17% from the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://www.galectintherapeutics.com

Peers: MEIP MNKD MNOV NERV

Key stats

What are the main financial stats of GALT

Market

Shares outstanding

61.9M

Market cap

$206.76M

Enterprise value

$252.84M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$41.89M

EBITDA

-$41.86M

Free cash flow

-$32.97M

Per share

EPS

-$0.74

Free cash flow per share

-$0.55

Book value per share

-$1

Revenue per share

TBVPS

$0.47

Balance sheet

Total assets

$28.2M

Total liabilities

$88.44M

Debt

$71.74M

Equity

-$61.96M

Working capital

$12.03M

Liquidity

Debt to equity

-1.16

Current ratio

1.77

Quick ratio

1.64

Net debt/EBITDA

-1.1

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-197.7%

Return on equity

N/A

Return on invested capital

-82%

Return on capital employed

-334.5%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

GALT stock price

How has the Galectin Therapeutics stock price performed over time

Intraday

-0.89%

1 week

-3.19%

1 month

17.19%

1 year

98.81%

YTD

101.2%

QTD

39.75%

Financial performance

How have Galectin Therapeutics's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$38.07M

Net income

-$44.69M

Gross margin

N/A

Net margin

N/A

The company's net income fell by 15% YoY

The operating income has grown by 2.7% since the previous quarter

Growth

What is Galectin Therapeutics's growth rate over time

Valuation

What is Galectin Therapeutics stock price valuation

P/E

N/A

P/B

N/A

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Galectin Therapeutics's EPS has decreased by 14% YoY but it has increased by 2.6% QoQ

GALT's equity has dropped by 83% year-on-year and by 18% since the previous quarter

Efficiency

How efficient is Galectin Therapeutics business performance

GALT's ROIC is up by 49% YoY and by 17% QoQ

The ROA has contracted by 26% YoY but it has grown by 9% from the previous quarter

Dividends

What is GALT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for GALT.

Financial health

How did Galectin Therapeutics financials performed over time

Galectin Therapeutics's total assets is 68% less than its total liabilities

The total liabilities has soared by 65% YoY and by 21% from the previous quarter

Galectin Therapeutics's total assets has increased by 32% YoY and by 27% from the previous quarter

GALT's equity has dropped by 83% year-on-year and by 18% since the previous quarter

The debt has soared by 80% YoY and by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.